Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.4.21.4 (trypsin)
42,187 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A kinin-potentiating peptide (KPP) generated from human plasma proteins on trypsin incubation was partially purified by ultrafiltration and ion-exchange chromatography and was characterized through some of its pharmacological properties. KPP itself was devoid of any action but it potentiated the guinea-pig ileum contractions elicited by several kinins, including an analog resistant to angiotensin-converting enzyme (ACE). In contrast, contractions induced by angiotensin II, histamine, acetylcholine, barium chloride and substance P were not potentiated. Not only did KPP have high specificity towards kinins, but its action started immediately and induced kinin potentiation in a dose-dependent and reversible manner. Furthermore KPP potentiated the bradykinin contracting effects on the rat uterus, a preparation with very poor ACE activity, and on guinea-pig ileum previously incubated with 1.10-phenanthroline, a metal chelator able to inhibit ACE and kininase I activities and with phosphoramidon, a specific inhibitor of neutral endopeptidase (NEP). The results suggest that the potentiating effect of KPP is due to a mechanism different from the inhibition of kinin metabolism by ACE, NEP and kininase I.
...
PMID:Pharmacological properties of a new kinin-potentiating peptide generated from human serum proteins. 260 51

A kallikrein-like kininogenase was identified in the rat adrenal gland. Most of the enzyme was present in an inactive form, since pre-incubation with trypsin markedly increased kininogenase activity from 54.8 +/- 11.8 to 230 +/- 23.0 pg bradykinin/mg protein/min. Adrenal kininogenase was inhibited 90% by phenyl methyl sulfonyl fluoride, 92% by D-Phe-Phe-Arg-chloromethylketone, 91% by aprotinin, and only 15% by soybean trypsin inhibitor. Pre-incubation with antibodies against rat urinary kallikrein resulted in 85% inhibition. The apparent molecular weight of adrenal kininogenase on gel filtration chromatography was 33 Kd. The enzyme was strongly adsorbed to immobilized rat urinary kallikrein antibodies and required drastic conditions for elution. In canine adrenal glands, we found that there was no difference in the cortical and medullary distribution of active and inactive SBTI resistant kininogenase activity. We conclude that an enzyme which closely resembles glandular kallikrein is present in adrenal glands.
...
PMID:Glandular kallikrein-like enzyme in adrenal glands. 261 63

A kininogen-like protein was purified from Bothrops jararaca plasma by DEAE-Sephadex ion-exchange and carboxy-methyl-papain-Sepharose affinity chromatography. The molecular weight, estimated by SDS-gel electrophoresis, is about 100,000 and a species of about 75,000 is formed after incubation with horse urinary kallikrein. After incubation with trypsin, only traces of biological activity were detected in tests on guinea pig ileum. The purified protein inhibits papain and bromelain, does not correct the clotting time of a kininogen-depleted human plasma, and does not affect the clotting time of plasma from Waglerophis merremii, a nonpoisonous snake; the same type of inhibitor was found in this nonpoisonous snake. The dissociation constant (Ki) for the papain-inhibitor complex is approximately 1.6 nM.
...
PMID:A Bothrops jararaca plasma cysteine-proteinase inhibitor related to mammalian kininogen. 263 47

The content of bradykinin (BK)-like peptides in rat dental pulp was significantly increased 1, 6 and 24 h after cavity formation at the neck of incisor. We have reported that enkephalin (EK)-like peptides in rat dental pulp were increased by cavity formation or BK. In the present study, the mechanism of the production of EK enhanced by BK was investigated using benzoyl-L-arginine-2-naphthylamide (BANA), a synthetic substrate. BK and its products cleft by carboxypeptidase B, des-Arg9-BK and arginine (Arg), activated the degradation of BANA. It is suggested that these substances may enhance the processing of enkephalins from precursor proteins. The activating effects were inhibited by EGTA. The BANA-degrading enzymes in lysosomal fraction were activated by BK, des-Arg9-BK and Arg, but the enzymes in supernatant were activated by Arg only. On the other hand, morphine and met-EK inhibited the production of BK-like peptides by trypsin from plasma kininogen. It is suggested that BK is cleft by carboxypeptidase B in pulp cell to des-Arg9-BK and Arg, which activate the lysosomal or soluble EK processing enzymes, and then the produced EK inhibits the production of BK from plasma kininogens in the pulp.
...
PMID:[Interaction between bradykinin and enkephalins in rat dental pulp]. 264 47

Endothelial injury has been proposed as a feature of a wide variety of vascular diseases, and release of endothelial lysosomal hydrolases could contribute to the pathological changes seen. We have determined the relative activities of 14 glycosidases, two esterases and four peptide hydrolases in human umbilical vein endothelial cells and investigated whether known agonists of endothelial function, or materials known to modulate hydrolase secretion in other phagocytic cells, influenced the activity or secretion of these enzymes by human umbilical vein endothelial cells. Hexosaminidase, beta-galactosidase, beta-glucuronidase and alpha-iduronidase accounted for most of the measured glycosidase activity. Acid phosphatase activity greatly exceeded arylsulphatase activity, and most of the measured peptidase activity was due to acid peptidases. Optimum pH and apparent Km values were determined for the most abundant hydrolases. Exposure of human umbilical vein endothelial cells to bradykinin, thrombin or interleukin-1 resulted in negligible release of either hexosaminidase or lactate dehydrogenase (LDH), in contrast to phorbol myristate acetate, which caused a parallel, dose-dependent release of both enzymes. Treatment of these cells with calcium ionophore A23187, trypsin or platelet-activating factor, caused less than 10% release of either hexosaminidase or LDH. Agents known to modulate lysosomal enzyme secretion by other phagocytic cells failed to induce selective secretion of lysosomal enzymes by human umbilical vein endothelial cells.
...
PMID:Lysosomal hydrolases of human vascular cells: response to agonists of endothelial function. 264 39

Limited proteolysis of T-kininogen by heterologous and homologous endopeptidases (bovine trypsin, human leukocyte elastase, rat submaxillary gland endopeptidase k, and rat mast cell chymase) produced similar fragmentation. Amino-terminal sequence analysis of whole T-kininogen lysates and purified proteolytic fragments identified four susceptible regions which contained all the preferential cleavage sites for these proteinases. Two of these susceptible regions were close to the junction between heavy chain cystatin-like domains, the third was in the kinin-containing region, and the fourth was close to the carboxyl terminus of the T-kininogen light chain. There was only one primary site for each proteinase in the kinin-containing region, which explains why catalytic amounts of these proteinases did not release immunoreactive kinin from this kininogen. However, preferential cleavage of T-kininogen close to the junction between cystatin-like domains released fragments which, provided they included cystatin-like domains 2 and/or 3, strongly inhibited papain and cathepsin L. The fragments were inhibitory even when parts of the amino-terminal ends of the domains were lacking. The highly conserved glycyl residue, thought to be involved in the inhibitory reactive site of cystatin-like inhibitors, was not required in purified domain 3 for inhibition of cathepsin L.
...
PMID:Limited proteolysis of T-kininogen (thiostatin). Release of comparable fragments by different endopeptidases. 264 33

We have developed a sensitive and specific radioimmunoassay which allows the detection of human glandular kallikrein in biologic fluids at a level of 40 pg/ml. The antisera did not recognize human plasma kallikrein and glandular kallikrein from other species including marmoset. Furthermore the antibody did not bind pro-kallikrein but was specific for the trypsin activated kallikrein. The antibody inhibited the kininogenase activity of standard kallikrein incubated with human kininogen. However active kallikrein inhibited by inhibitors bound at the active site is still detectable, indicating that the antibody is specific for the structure of the active form but not for the active site. In normotensive subjects, daily urinary kallikrein excretion increased with age until 30, then a decrease was observed. In renal transplanted recipients a progressive increase of the active form was found. A low concentration of immunoreactive active kallikrein was detected in lymphatic fluids of patients suffering from acute pancreatitis treated by lymphatic drainage; although this kallikrein is the active immunoreactive form, a very weak kininogenase activity was measured, suggesting a partial inhibition by anti-proteases. These data provide complementary evidence for the physiological and pathological role of glandular kallikrein.
...
PMID:Direct radioimmunoassay of active and inactive human glandular kallikrein: some physiological and pathological variabilities. 266 24

In the present study, a significant positive correlationship was found between the contents of bradykinin (BK)-like and met-enkephalin(ME)-like peptides in adrenal medulla of the rat with cavity-formed incisors in vivo, and the production of ME-like peptides was increased by BK in adrenal medulla of the rat in vitro. Influence of BK on the degradation of BANA, a synthetic substrate for trypsin, by the tissue enzymes was also studied. It was found that BK (0.1-10 microM) enhanced the enzyme activities in a dose-dependent manner, and the effect of BK(1 microM) was most effective at pH 6 and 8. The BK effect was inhibited by FOY-305, an inhibitor of serine proteinases, at pH 6, but not at pH 8. However, E-64, an inhibitor of cysteine proteinases, reduced the BK effects at both pH 6 and 8. These results suggested that 1) BK was an activator for BANA-degrading enzymes which were thought as processing proteinases of ME-like peptides in adrenal medulla of the rat, and 2) there may be, at least, two kinds of BANA-degrading enzymes activated by BK, one might be a serine proteinase with optimal pH at 6, and the others might be cysteine proteinases with optimal pH at both 6 and 8.
...
PMID:Enhancement of proteinase activities by bradykinin in adrenal medulla of the rat. 269 19

Kallidinogenase preparations were investigated with a view of comparing their quality by the enzymological method. These studies were carried out on 13 types of preparations (tablet: 7 kinds, capsule: 3 kinds, ampoule: 3 kinds) of commercially available kalliginogenase preparations. The kinin-liberating activity per one international unit (IU) of kallidinogenase was approximately 400 ng bradykinin/min/IU. The contents of other enzymes, i.e., kininase, trypsin and protease, were determined as the impurities. Kininase, trypsin and protease activities in the preparations for injection were very low. However, one preparation for internal use contained large amounts of these enzyme as impurities. It was presumed that contamination with large amounts of kininase, trypsin and protease have an adverse influence upon the assay and stability and efficacy of these preparations.
...
PMID:[Studies on the quality of enzyme preparations (IX)--kallidinogenase preparations]. 270 78

Glandular kallikrein is known to promote contractions of the isolated, estrogenized rat uterus, perhaps independently of kinin formation. The recent availability of kinin receptor antagonists led us to study whether they might affect the oxytocic activity of kallikrein. DArg0-Hyp3-Thi5,8-DPhe7-bradykinin (8.5 x 10(-7) M) displaced the dose-response curves to both bradykinin (from 1.0 x 10(-9) to 4.0 x 10(-6) M) and kallikrein (from 4.7 x 10(-11) to 8.0 x 10(-9) M) approximately one order of magnitude to the right. This inhibition could not be due to a nonspecific effect on the uterine muscle, as the contractile response to oxytocin was not altered. In addition, carboxypeptidase B (a potent kininase) and kinin antibodies reduced the contractile response to kallikrein by 70 and 60%, respectively. Removal of the intervening agent restored the normal response. The effect of kallikrein depended on its enzymatic activity, inasmuch as kallikrein inactivated with D-Phe-Arg-Arg-CH2Cl was not oxytocic. Prolonged or multiple exposures to kallikrein completely abolished uterine response, whereas the effect of bradykinin was unaltered. Uterine horns rendered insensitive to kallikrein by prolonged exposure still contracted in response to trypsin. Kininogen was present in the uterine tissue in a concentration of 1.5 +/- 0.3 ng of bradykinin equivalents per mg wet wt. No more than 15.9 +/- 1.2% of this total was due to plasma contamination. Only 21.5 +/- 2.9% of total kininogen could be cleaved by kallikrein. We conclude that part of the oxytocic activity of kallikrein is related to generation of kinins from a kallikrein-sensitive kininogen present in the isolated rat uterus.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Kinins contribute to the contractile effects of rat glandular kallikrein on the isolated rat uterus. 272 35


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>

---